Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Regules

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Infectious Diseases|February 8, 2024
Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria ChallengeDeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, et al.
The Lancet. Microbe|February 15, 2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyMelinda J Hamer, James M McCarty, Benjamin C Pierson, et al.
Frontiers in Immunology|May 16, 2020
The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria InfectionYing Du, Ethan G Thompson, Julius Muller, et al.
Vaccine|February 14, 2022
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adultsKristopher M Paolino, Jason A Regules, James E Moon, et al.
Plos Pathogens|March 28, 2022
A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparumNathan Beutler, Tossapol Pholcharee, David Oyen, et al.
Frontiers in Big Data|July 2, 2021
Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection TrialsWilliam Chad Young, Lindsay N Carpp, Sidhartha Chaudhury, et al.
Nature Medicine|January 3, 2024
A candidate antibody drug for prevention of malariaKatherine L Williams, Steve Guerrero, Yevel Flores-Garcia, et al.
The Journal of Infectious Diseases|June 15, 2016
Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity StudyJason A Regules, Susan B Cicatelli, Jason W Bennett, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Infectious Diseases|February 8, 2024
Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria ChallengeDeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, et al.
The Lancet. Microbe|February 15, 2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyMelinda J Hamer, James M McCarty, Benjamin C Pierson, et al.
Frontiers in Immunology|May 16, 2020
The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria InfectionYing Du, Ethan G Thompson, Julius Muller, et al.
Vaccine|February 14, 2022
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adultsKristopher M Paolino, Jason A Regules, James E Moon, et al.
Plos Pathogens|March 28, 2022
A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparumNathan Beutler, Tossapol Pholcharee, David Oyen, et al.
Frontiers in Big Data|July 2, 2021
Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection TrialsWilliam Chad Young, Lindsay N Carpp, Sidhartha Chaudhury, et al.
Nature Medicine|January 3, 2024
A candidate antibody drug for prevention of malariaKatherine L Williams, Steve Guerrero, Yevel Flores-Garcia, et al.
The Journal of Infectious Diseases|June 15, 2016
Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity StudyJason A Regules, Susan B Cicatelli, Jason W Bennett, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Pageof 3